MARKET

FATE

FATE

Fate Therapeutic
NASDAQ
2.110
+0.020
+0.96%
After Hours: 2.128 +0.018 +0.87% 19:59 10/23 EDT
OPEN
2.080
PREV CLOSE
2.090
HIGH
2.135
LOW
2.015
VOLUME
1.11M
TURNOVER
--
52 WEEK HIGH
3.230
52 WEEK LOW
0.9500
MARKET CAP
252.82M
P/E (TTM)
-2.0038
1D
5D
1M
3M
1Y
5Y
1D
Wedbush Sticks to Their Buy Rating for Fate Therapeutics (FATE)
TipRanks · 6d ago
Weekly Report: what happened at FATE last week (1012-1016)?
Weekly Report · 6d ago
Press Release: Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies
Dow Jones · 10/12 11:00
Weekly Report: what happened at FATE last week (1005-1009)?
Weekly Report · 10/12 10:17
Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX)
TipRanks · 10/07 14:00
Analysts Conflicted on These Healthcare Names: Dexcom (DXCM) and Fate Therapeutics (FATE)
TipRanks · 10/05 11:20
Weekly Report: what happened at FATE last week (0928-1002)?
Weekly Report · 10/05 10:17
Fate Therapeutics (FATE) Securities Case Faces Another Motion to Dismiss After 2025 Dismissal Order
TipRanks · 10/02 09:11
More
About FATE
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing off-the-shelf, multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. The Company's pipeline includes iPSC-derived, chimeric antigen receptor (CAR)-targeted T-cell and NK cell product candidates. The iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. The Company's product candidates under development include FT819, FT522, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT825 is its first iPSC-derived CAR T-cell product candidate for the treatment of solid tumors being developed in collaboration with Ono Pharmaceutical. FT836 is the Company's multiplexed-engineered CAR T-cell product candidate targeting MHC proteins MICA and MICB.

Webull offers Fate Therapeutics Inc stock information, including NASDAQ: FATE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FATE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FATE stock methods without spending real money on the virtual paper trading platform.